Opportunity in Sun Pharma, prefer midcap IT: Amit Khurana

Amit Khurana of Dolat Capital Market told CNBC-TV18, "Within IT, we have a more neutral stand with a tactical positive view. We definitely like some of the midcap names. We believe that largecaps will have some potential. In general, we believe that the midcaps having corrected quite meaningfully over the last few months will have a potential. That remains our bias on IT services.""Within pharmaceutical, it is a very stock specific call that you would probably have to take. So, we definitely believe there was a tactical opportunity in Sun Pharmaceutical Industries after the sharp correction that it did see. We do believe some of the midcap names which are building capabilities on their research and development (R&D) side and on the product side by going through the US Food and Drug Administration (FDA) filings will definitely be worthwhile to watch out for," he said. "So, our pharmaceutical call is more stock specific while in IT we prefer the midcap names more so."Disclosure: Analyst may have personal holdings.